Insulin oral - Puredel

Drug Profile

Insulin oral - Puredel

Alternative Names: Ossulin

Latest Information Update: 14 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Puredel
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Clinical Phase Unknown Diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 13 Nov 2009 Puredel intends to out-licence Ossulin™ after proof of principle studies (http://www.cmdpharmaltd.com/ossulin.asp)
  • 13 Nov 2009 Clinical trials in Diabetes mellitus in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top